Compare Pfizer Inc (PFE) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Charles Schwab Corporation Common Stock — how do they compare? Pfizer Inc trades at $27.99 (market cap $158.56B), while Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B). The key difference: Pfizer Inc and Charles Schwab Corporation Common Stock are close in size by market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| PFE | SCHW | |
|---|---|---|
Market Cap | $158.56B | $167.52B |
Volume | 44,138,282 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $29.02 | $113.65 |
52-Week Low | $23.67 | $85.35 |
Typical Hold Time | 158 Days | 85 Days |
Enterprise Value | $210.06B | $153.97B |
Dividend Yield | 6.18% | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Charles Schwab (SCHW) trades at $95.58, down 1.26% today, amid bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $1.62 exceeding expectations of $1.56, while revenue grew to $23.92B in 2025. Analyst consensus remains bullish with a $119.92 price target, though technical indicators show selling pressure with RSI at oversold levels and bearish moving average alignment.
SCHW presents a compelling value opportunity with attractive valuation metrics (P/E 17.64) and robust profitability (ROE 22.45%), but faces near-term technical headwinds and market volatility risks. The company's expansion into AI integration and Texas Stock Exchange listing provides growth catalysts, though investors should monitor interest rate sensitivity and competitive pressures in the brokerage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
